Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Humboldt Fund
BioCentury | Jan 6, 2024
Finance
Jan. 5 Quick Takes: Metagenomi, ArriVent file for IPO
Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis
BioCentury | Jan 27, 2023
Finance
Jan. 26 Quick Takes: Grey Wolf bringing neoantigen-booster to the clinic with $49M B round
Plus: Keytruda approved for adjuvant NSCLC and updates for AZ’s Evusheld, BMS’s Breyanzi, Magenta, Theonys and more
BioCentury | Jun 4, 2022
Regulation
June 3 Quick Takes: myocarditis risk weighs on Novavax stock
Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health
BioCentury | Apr 12, 2022
Emerging Company Profile
Ansa debuts with $68M series A for enzymatic DNA synthesis, hold the blocking groups
By using enzyme-cleavable linkers instead of blocking groups, Ansa can generate long, undamaged DNA molecules
BioCentury | Mar 26, 2022
Emerging Company Profile
Affini-T: engineering T cells to target oncogenic drivers in solid tumors
With $175M in the bank, Fred Hutch spinout is adding synthetic biology switches to T cells to increase their tumor infiltration and persistence
BioCentury | Jan 26, 2022
Emerging Company Profile
Cellino: Automating complex production, differentiation of iPS cells into cell therapies
Via $80M A round for manufacturing play, Bayer deepens its reach into next-gen cell therapy technologies
BioCentury | Jan 26, 2022
Product Development
$175M series B gives Metagenomi runway to deliver deals, programs to clinic
PFM, Farallon lead Bay Area biotech’s round to support pipeline, expand reach of gene editing systems
BioCentury | Apr 8, 2021
Finance
Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra
Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant
BioCentury | Feb 2, 2021
Deals
Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more
Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and
BioCentury | Nov 14, 2020
Emerging Company Profile
Metagenomi hunts for new gene editing systems with $65M series A
Emerging Company Profile: Bay Area newco debuts with round led by Leaps by Bayer and Humboldt Fund
Items per page:
1 - 10 of 12